Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365620 | 0.90 | HTR2C (0.43) | HTR2CHTR2AWNT3AHTR2BCYP1A2 | |
| SCHEMBL19670512 | 0.87 | BTK (0.37) | WNT3A | |
| SCHEMBL19670405 | 0.86 | BRAF (0.40) | WNT3A | |
| SCHEMBL19670179 | 0.85 | HTR2C (0.46) | HTR2CHTR2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL19670393 | 0.85 | ABL1 (0.42) | HTR2CHTR2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL19670388 | 0.85 | CACNA1G (0.46) | HTR2CHTR2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL19670352 | 0.85 | HTR2C (0.47) | HTR2CHTR2AHTR2B | |
| SCHEMBL19670589 | 0.83 | HTR2C (0.42) | HTR2CHTR2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL19670527 | 0.83 | NAMPT (0.46) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19669970 | 0.82 | PIK3CA (0.36) | WNT3AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4649/4885HTR2A 4359/4885WNT3A 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.